title: Pharmacotherapy of idiopathic generalized epilepsies.
abstract: BACKGROUND
  Idiopathic generalized epilepsies (IGE) represent about 20% of all epilepsies, are genetically determined and comprise several subgroups of syndromes. Although complete seizure control is achievable in about 80% of patients with IGE syndromes, a substantial group remains with inadequate control and unsatisfactory long-term outcome. Several new antiepileptic drugs (AEDs) have been studied in children with IGE.
  
  
  OBJECTIVE
  To review the rational drug choice for these patients, the PubMed database was searched with the keywords IGE and AEDs.
  
  
  RESULTS
  Older AEDs continue to play a major role in the treatment of IGE. Although the first line monotherapy is still with sodium valproate, new drugs like lamotrigine, levetiracetam and topiramate, are increasingly used in the treatment of IGE.
  
  
  CONCLUSIONS
  Further research on evidence-based treatment of IGE with new AEDs is needed. New data from molecular genetics of IGE might have the potential to help clinicians choose the most appropriate antiepileptic therapy.
authors.affiliation: Tor Vergata University, Pediatric Neurology Unit, Department of Neurosciences, Rome, 00133, Italy. curatolo@uniroma2.it
authors.forename: Paolo
authors.initials: P
authors.lastname: Curatolo
authors.forename: Romina
authors.initials: R
authors.lastname: Moavero
authors.forename: Adriana
authors.initials: A
authors.lastname: Lo Castro
authors.forename: Caterina
authors.initials: C
authors.lastname: Cerminara
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004829:Epilepsy, Generalized / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics; D006801:Humans; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants